SCHEMBL22040155

SCHEMBL22040155

Cn1ccnc1C(=O)CCCNC(=O)OC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.43
▸ STK17B O94768 1/20 0.42
▸ STK17A Q9UEE5 1/20 0.42
▸ SIGMAR1 Q99720 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CA1 P00915 7/20 0.41
▸ CA2 P00918 7/20 0.41
▸ CA12 O43570 4/20 0.41
▸ CA9 Q16790 4/20 0.41
▸ DYRK1A Q13627 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ DRD2 P14416 2/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GFER P55789 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8232530 0.84 KDM4E (0.39) TDP1STK17BSTK17ASIGMAR1CA1
SCHEMBL23745232 0.79 STING1 (0.39) MEN1KMT2AKDM4EPOLBALDH1A1
SCHEMBL18787644 0.77 NAMPT (0.39) GAAKMT2AKDM4EALDH1A1
SCHEMBL2084315 0.77 MAOA (0.47) TDP1STK17BSTK17AMEN1GAA
SCHEMBL10178069 0.76 ALDH1A1 (0.54) TDP1STK17BSTK17AMEN1GAA
SCHEMBL7056763 0.75 STK17B (0.45) TDP1STK17BSTK17AMEN1GAA
SCHEMBL2084610 0.75 TDP1 (0.44) TDP1STK17BSTK17AMEN1GAA
SCHEMBL15979655 0.74 NAMPT (0.44) MEN1GAAKMT2APOLBALDH1A1
SCHEMBL28420219 0.74 KDM4E (0.43) TDP1STK17BSTK17AMEN1GAA
SCHEMBL22039513 0.73 TDP1 (0.44) TDP1STK17BSTK17AMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3889138-B1 HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF HINOVA PHARMACEUTICALS INC (CN) 2024-11-20 — — EP disclosed
US-20220087996-A1 Histone acetylase p300 inhibitor and use thereof HINOVA PHARMACEUTICALS INC. (CN) 2022-03-24 — — US disclosed
EP-3889138-A1 HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF Hinova Pharmaceuticals Inc. (CN) 2021-10-06 — — EP disclosed
EP-3889138-A1 HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF Hinova Pharmaceuticals Inc. (CN) 2021-10-06 — — EP disclosed
WO-2020108500-A1 HISTONE ACETYLASE P300 INHIBITOR AND USE THEREOF 成都海创药业有限公司 2020-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220087996-A1 Histone acetylase p300 inhibitor and use thereof EP300, HDAC1, HDAC11 TDP1 1516/4885STK17B 1273/4885STK17A 1062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback